NCT05860530View on ClinicalTrials.gov

Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

September 8, 2021

Study Completion Date

September 8, 2021

Conditions
Neoplasms
Interventions
DRUG

The test olaparib tablet (T)

The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours

DRUG

The reference olaparib tablet (R)

The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours

Trial Locations (1)

233004

The First Affiliated Hospital of Bengbu Medical College, Bengbu

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY